Cipher Pharmaceuticals (TSE:CPH) Price Target Raised to C$19.00 at Stifel Nicolaus

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR had its price target boosted by stock analysts at Stifel Nicolaus from C$17.00 to C$19.00 in a research note issued to investors on Thursday, BayStreet.CA reports. Stifel Nicolaus' price objective would indicate a potential upside of 17.65% from the company's previous close.

A number of other equities analysts have also commented on CPH. Leede Financial lowered shares of Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 13th. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 12th.

Cipher Pharmaceuticals Stock Down 2.0 %

Cipher Pharmaceuticals stock traded down C$0.33 during mid-day trading on Thursday, hitting C$16.15. 16,650 shares of the company's stock were exchanged, compared to its average volume of 46,755. Cipher Pharmaceuticals has a 1-year low of C$4.30 and a 1-year high of C$19.69. The stock has a 50 day moving average of C$16.40 and a two-hundred day moving average of C$11.74. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The stock has a market cap of C$413.28 million, a P/E ratio of 13.02 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last issued its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, beating analysts' consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The business had revenue of C$7.26 million for the quarter, compared to analyst estimates of C$7.52 million. As a group, analysts anticipate that Cipher Pharmaceuticals will post 1.6472868 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.